List view / Grid view
An AI tool has identified adalimumab, a drug used for arthritis and Crohn’s disease, as a life-saving treatment for rare Castleman’s disease (iMCD). This finding offers hope for patients with the condition.
Study reveals how type 2 diabetes accelerates cognitive decline by damaging white matter in the brain. Sam Hashemi at Prenuvo explains how advanced AI and whole-body MRI technology are opening new possibilities for early intervention.
A new AI-powered approach is tackling the challenge of 'undruggable' diseases by designing peptides that can bind to and destroy previously untreatable proteins.
UVA researchers found that continuous glucose monitor data can predict nerve, eye, and kidney damage in type 1 diabetes.
In part two of the step-by-step scientific workflow for drug discovery series, Dr Raminderpal Singh and Nina Truter describe the functions of the workflow previously outlined and include key considerations.
MIT's new open-source AI model, Boltz-1, could transform drug discovery by accurately predicting protein structures, offering global access to researchers.
AI is set to transform drug development in 2025, streamlining processes and opening new possibilities. Learn how this technology is transforming clinical trials and reshaping the pharmaceutical industry.
Refeyn's new software automates mass photometry workflows, delivering faster and more consistent results for bioanalytical applications.
Tune in to this episode to learn how overcoming the key challenges in personalised medicine could transform the future of healthcare.
To fully unlock the potential of immunotherapy for cancer patients, we need better targets, not just better treatments. Hear from Michelle Teng, CEO of Etcembly, on how AI is decoding the immune repertoire and designing new therapies.
Insilico Medicine’s AI-designed drug ISM5939 has received FDA IND clearance for treating solid tumours. By targeting ENPP1, it enhances anti-tumour immunity and is set to begin Phase I trials soon.
The path to faster breakthroughs in precision medicine begins with overcoming the complexities of multi-modal data. Discover how innovative solutions are enabling more personalised treatments.
Based on MRI scans from 732 prostate cancer patients, the AI model identified the edges of 85 percent of the most radiologically aggressive lesions.
In this article, Dr Raminderpal Singh speaks to Neil Wilkie of Mironid Ltd. for a biotech CEO’s perspective on the transformative potential of AI, and the importance of bridging communication gaps between scientific and technical teams to drive innovation and efficiency in the pharmaceutical industry.
Proscia has launched two new products which will help to accelerate discovery and development of new therapies and diagnostics.
